Document:

Addendum to Stock Option Agreement

 Exhibit 10.72 
  
 Dale L. Fuller Stock Option Addendum Dated February 2, 2005 
  
 ADDENDUM 
 TO 
 STOCK OPTION AGREEMENT 
  
 The following provisions are hereby incorporated into, and are hereby made a
part of, that certain Stock Option Agreement (the “Option Agreement”) by and between Borland Software Corporation (the “Corporation”) and Dale L. Fuller (“Optionee”) evidencing the stock option granted on February 2,
2005 (the “Option”) and granted to Optionee under the terms of the Corporation’s 2002 Stock Incentive Plan, and such provisions are effective immediately. All capitalized terms in this Addendum, to the extent not otherwise defined
herein, shall have the meanings assigned to them in the Option Agreement. 
  
 SPECIAL ACCELERATION AND POST-TERMINATION EXERCISE PERIOD 
  
 1. If (i) the Corporation terminates Optionee’s status as an Employee for any reason other than for Cause, as such term is defined in Optionee’s
Employment Agreement dated January 1, 2001 (the “Employment Agreement”) or (ii) Optionee terminates Optionee’s status as an Employee as a result of Optionee’s Constructive Termination (as defined in the Employment Agreement),
then the Option shall become fully vested and exercisable and may be exercised for all unexercised Option Shares. 
  
 2. In the event of a Change in Control of the Corporation, all unexercised Option Shares shall become fully vested and exercisable as of the date ten (10)
days prior to the date of the Change in Control. Such vested Option Shares shall be exercisable for the whole ten (10) day period; provided, however, that any Option Shares subject to the Option that become vested solely based on this paragraph
shall have such vesting conditioned upon on the consummation of the Change in Control. To the extent the Option is not fully exercised as of the consummation of the Change in Control, the Option shall be subject to Article Two, Section IV of the
Plan. 
  
 3. The Option shall remain exercisable until the earlier
of (i) the Expiration Date (as defined in the Option Agreement) and (ii) the expiration of the twenty-four (24) month-period measured from the date of the termination of Optionee’s Service for any reason. 
  
 4. The provisions of Paragraphs 1 and 2 of this Addendum shall govern the
vesting of the Option in the event of (i) a termination of Optionee’s status as an Employee upon a termination by the Company without Cause or upon a Constructive Termination and (ii) a Change in Control, and shall supersede any provisions to
the contrary in the Grant Notice or Option Agreement. The provisions of Paragraph 3 of this Addendum shall govern the period for which the Option is to remain exercisable, and shall supersede any provisions to the contrary in the Option Agreement,
including Sections 5(a) through 5(d) of the Option Agreement. 
  
 5. In the event of any conflict, ambiguity, or inconsistency between the provisions of the Option Agreement and the provisions of this Addendum, to the extent possible such provisions will be interpreted so as to resolve any such conflict,
ambiguity, or inconsistency, and if that is not possible, the provisions of the this Addendum will prevail. 

 Dale L. Fuller Stock Option Addendum Dated February 2, 2005 
  
 IN WITNESS WHEREOF, Borland Software Corporation has caused this
Addendum to be executed by its duly authorized officer as of the Effective Date specified below. 
  

			
	BORLAND SOFTWARE CORPORATION
		
	By:	 	 /s/ Timothy J. Stevens

	Title:	 	 Sr. Vice President, General Counsel and
 Corporate
Secretary

  

	
	 EFFECTIVE DATE: February 2, 2005

	
	 ACCEPTED AND AGREED:

	
	 /s/ Dale L. Fuller

	 Dale L. Fuller, OPTIONEESupplemental Indenture Number 1

 Exhibit 4.1 
  
 Executed Copy 
  
 VIROPHARMA INCORPORATED 
  
 To 
  
 U.S. BANK NATIONAL ASSOCIATION, 
  
 as Trustee 
  

  
 SUPPLEMENT NUMBER 1 
  
 Dated as of 
  
 May 6, 2005 
  
 TO 
  
 CONVERTIBLE NOTES INDENTURE 
  
 Dated as of 
  
 October 18, 2004 
  

  
 6% Convertible Senior Secured Notes due
2009 

 SUPPLEMENTAL INDENTURE NUMBER 1 
  
 SUPPLEMENTAL INDENTURE NUMBER 1 (the “Supplement”), dated as of May 6, 2005, to the Convertible Notes
Indenture, dated as of October 18, 2004 (the “Indenture”), between ViroPharma Incorporated, a Delaware corporation (hereinafter called the “Company”), having its principal office at 397 Eagleview Boulevard, Exton,
Pennsylvania 19341, and U.S. Bank National Association, as trustee hereunder (hereinafter called the “Trustee”), having its principal corporate trust office at One Federal Street, 3rd Floor, Boston, Massachusetts 02110. Capitalized terms used and not otherwise defined in this Supplement shall have the respective meanings ascribed to such
terms in the Indenture. 
  
 WITNESSETH: 
  
 WHEREAS, the Company desires to add to and change certain provisions of the
Indenture; 
  
 WHEREAS, pursuant to Section 11.2 of the Indenture,
the Company and the Trustee may enter into an indenture or indentures supplemental thereto for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of the Indenture or any supplemental indenture or
of modifying in any manner the rights of the holders of the Notes with the consent of not less than a majority of aggregate principal amount of the Notes then outstanding and when the Company is so authorized by resolution of its Board of Directors
(collectively, the “Requisite Noteholders”); 
  
 WHEREAS, the Financing Committee, which was duly authorized by the Company’s Board of Directors and authorized to act for it under the Indenture, has adopted the resolutions attached hereto as Exhibit A authorizing, and the
Requisite Noteholders have consented to, this Supplement; 
  
 WHEREAS, the Company directs the Trustee to enter into this Supplement; 
  
 NOW, THEREFORE, the Company covenants and agrees with the Trustee for the equal and proportionate benefit of the respective holders from time to time of the Notes (except as otherwise provided below) as follows:

  
 1. Section 1.1 of the Indenture is hereby amended and
supplemented by adding the following defined terms: 
  
 (a)
“Additional Notes” means up to $12,500,000 of additional Notes issuable at the option of the Buyers (or their respective permitted assigns) pursuant to Section 1(a) of the Purchase Agreement. 
  
 (b) “Additional Registration Statement” means a registration
statement or registration statements by the Company under the Securities Act registering the resale of the Additional Notes and the Common Stock issuable upon any conversion of the Additional Notes. 
  
 (c) “Initial Notes” means the $62,500,000 aggregate
principal amount of Notes issued at the Effective Exchange Time. 
  

 -2- 

 (d) “Initial Registration Statement” means a registration statement or registration
statements by the Company under the Securities Act registering the resale of the Initial Notes and the Common Stock issuable upon any conversion of the Initial Notes. 
  
 2. Section 5.15(b) of the Indenture is hereby amended and restated to be and read as follows: 
  
 “(b) The Company’s obligations pursuant to Section 5.15(a) shall
automatically expire and terminate upon the first to occur of: (i) the close of business on the first date during which any conversion of any Note results in at least two-thirds of the aggregate principal amount of Notes issued under this Indenture
to have been converted into Common Stock since the date of this Indenture, or (ii) the date which is forty-five (45) days after the close of business on the Trading Day which is the 20th Trading Day during which the daily volume-weighted average price of the Common Stock has exceeded 150% of the Conversion Price then in effect under this
Indenture during any 30 Trading Day period; provided, that a registration statement or registration statements for resale of the Convertible Notes and the Conversion Shares shall have been effective with the United States Securities and Exchange
Commission for each of the twenty (20) Trading Days; or (iii) the close of business on September 7, 2005.” 
  
 3. Clause (x) of Section 15.12(a) of the Indenture is hereby amended and restated to be and read as follows: 
  
 “(x) an Initial Registration Statement is effective and available for
use on the date selected by the Company for Auto-Conversion (such date being the date on which the Auto-Conversion is deemed effective under this Indenture and which is herein referred to as the “Auto-Conversion Date”) if only the
Initial Notes have been issued under this Indenture or an Initial Registration Statement and Additional Registration Statement are effective and available for use on the Auto-Conversion Date if both the Initial Notes and the Additional Notes have
been issued under this Indenture or” 
  
 4. This Supplement
may be executed in any number of counterparts, each of which shall be an original, but such counterparts shall together constitute but one and the same instrument. 
  
 5. Except as amended and supplemented by this Supplement, the Indenture is hereby ratified and confirmed in all respects and
shall remain in full force and effect without change. 
  
 6. This Supplement shall become effective on the date on which the Company first receives executed consents of the Requisite Noteholders. 
  
 7. The Trustee shall not be responsible in any manner whatsoever or in respect of the validity or sufficiency of this Supplement or for or in respect of
the recitals contained herein, all of which recitals are made solely by the Company. 
  

 -3- 

 8. All agreements in this Supplement shall bind the Company and its successors and all agreements of the
Trustee in this Supplement shall bind its successors. 
  
 [Remainder of page intentionally left blank] 
  

 -4- 

 U.S. Bank National Association hereby accepts the trusts in this Supplement declared and provided, upon
the terms and conditions herein above set forth. 
  
 IN WITNESS
WHEREOF, the parties hereto have caused this Supplement to be duly executed. 
  

			
	VIROPHARMA INCORPORATED
		
	By:	 	 /s/ Vincent J. Milano

	Name:	 	Vincent J. Milano
	Title:	 	Vice President, Chief Financial Officer
	
	U.S. BANK NATIONAL ASSOCIATION,
	as Trustee
		
	By:	 	 /s/ Alison D.B. Nadeau

	Name:	 	Alison D.B. Nadeau
	Title:	 	Vice President

  
 [Company and
Trustee Signature Page]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00084-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00084-of-00352.parquet"}]]